C3A serum-free clonal cell line and methods of use
View Patent ↗A serum-free C3A clonal cell line and methods for generating the same are provided. The C3A cell line has a reduced doubling time in serum-free medium compared to a corresponding C3A cell line from which it is derived. Methods using the cells of the serum-free C3A clonal cell line for the production, expression and recovery of harvestable polypeptides, screening compounds for metabolic activity, studying enteric disease and for use in a bio-artificial liver device are also provided.
1. An extracorporeal bio-artificial liver device comprising an apparatus containing cells of the cell line deposited as ATCC accession No. CRL-12461, wherein the cells have a doubling time in serum-free medium which is less than about 70% of the doubling time in serum-free medium for C3A cells, wherein the cells are cultured in serum-free medium on a surface in the device and express one or more proteins selected from the group consisting of albumin, alpha-1-antitrypsin, factor V, complement C3, antithrombin III, and transferrin, and wherein the surface is contained within a hollow fiber cartridge, wherein the hollow fiber is formed from a membrane which has a pore size of about 0.1 μm to 0.3 μm, and wherein the cartridge is at least 1400 cm 2 .
2. A method of using cells of the cell line deposited as ATCC accession No. CRL-12461, wherein the cells have a doubling time in serum-free medium which is less than about 70% of the doubling time in serum-free medium for C3A cells in an extracorporeal bio-artificial liver device, comprising:
a) providing the cells to a surface in the device, wherein the device comprises a hollow fiber cartridge formed from a membrane which has a pore size of about 0.1 μm to 0.3 μm, and wherein the cartridge is at least 1400 cm 2 ;
b) culturing the cells in the device in serum-free medium;
c) attaching the extracorporeal device to a subject between an artery and vein of the subject, wherein the device is in fluid communication with the artery and vein; and
d) perfusing blood from the subject through the attached device,
wherein the cultured cells interact with the blood to provide serum free liver bio-products to the blood of the subject, wherein the bio-products are selected from the group consisting of albumin, alpha-1-antitrypsin, factor V, complement C3, antithrombin III, and transferrin.
3. A method of providing serum free liver bio-products to a subject, comprising:
a) providing cells of the cell line deposited as ATCC accession No. CRL-12461, wherein the cells have a doubling time in serum-free medium which is less than about 70% of the doubling time in serum-free medium for C3A cells to a surface in an extracorporeal bio-artificial liver device, wherein the cells express one or more liver bio-products selected from the group consisting of albumin, alpha-1-antitrypsin, factor V, complement C3, antithrombin III, and transferrin,
b) culturing said cells in said device in serum-free medium, wherein the device comprises a hollow fiber cartridge formed from a membrane which has a pore size of about 0.1 μm to 0.3 μm, and wherein the cartridge is at least 1400 cm 2 ; and
c) perfusing blood from said subject through the device to contact said cells,
wherein the perfusing results in release of protein and low molecular weight products from said cells into blood exiting said device.
4. The method of claim 3 , wherein the subject is awaiting liver transplantation.
5. The method of claim 4 , wherein the protein is albumin.
6. The method of claim 3 , wherein said subject is a human.